William Wierda, MD Anderson Cancer Center, Houston, US, discusses the impact of novel treatment options on long-term outcomes in chronic lymphocytic leukemia (CLL). He discusses the new standard-of-care of small molecule inhibitor monotherapy, and/or with a CD20 antibody. He also mentions the exciting data on combination approaches utilizing BCL-2 inhibitors with BTK inhibitors which have been shown to induce very good deep remissions in the majority of patients, so much so that it may be possible to consider discontinuing therapy.
The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.